Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics-Reference-Cited by-同舟云学术

Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics

Published:2022-02 Issue: Volume:76 Page:103856
ISSN:2352-3964
Container-title:eBioMedicine
language:en
Short-container-title:eBioMedicine

Author:

Quinn Tom M.^ORCID,Gaughan Erin E.^ORCID,Bruce Annya,Antonelli Jean,O'Connor Richard,Li Feng,McNamara Sarah,Koch Oliver^ORCID,MacKintosh Claire,Dockrell David,Walsh Timothy,Blyth Kevin G.,Church Colin,Schwarze Jürgen,Boz Cecilia,Valanciute Asta,Burgess Matthew,Emanuel Philip,Mills Bethany^ORCID,Rinaldi Giulia,Hardisty Gareth,Mills Ross,Findlay Emily Gwyer,Jabbal Sunny,Duncan Andrew^ORCID,Plant Sinéad,Marshall Adam D.L.,Young Irene,Russell Kay,Scholefield Emma,Nimmo Alastair F.^ORCID,Nazarov Islom B.,Churchill Grant C.,McCullagh James S.O.^ORCID,Ebrahimi Kourosh H.,Ferrett Colin,Templeton Kate,Rannard Steve,Owen Andrew,Moore Anne,Finlayson Keith,Shankar-Hari Manu^ORCID,Norrie John,Parker Richard A.,Akram Ahsan R.^ORCID,Anthony Daniel C.^ORCID,Dear James W.,Hirani Nik,Dhaliwal Kevin

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference35 articles.

1. Novel Coronavirus – China,2020

2. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis;Shankar-Hari;Jama,2021

3. Dexamethasone in hospitalized patients with Covid-19;Group;New England Journal of Medicine,2020

4. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial;Abani;The Lancet,2021

5. Identification of nafamostat as a potent inhibitor of middle east respiratory syndrome coronavirus s protein-mediated membrane fusion using the split-protein-based cell-cell fusion assay;Yamamoto;Antimicrob Agents Chemother,2016

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pathophysiological dynamics in the contact, coagulation, and complement systems during sepsis: Potential targets for nafamostat mesilate;Journal of Intensive Medicine;2024-10

2. TMPRSS2 inhibitors for the treatment of COVID-19 in adults: a systematic review and meta-analysis of randomized clinical trials of nafamostat and camostat mesylate;Clinical Microbiology and Infection;2024-06

3. The Effectiveness and Safety of Nafamostat Mesylate in the Treatment of COVID-19: a Meta-Analysis;Japanese Journal of Infectious Diseases;2024-05-31

4. Individual Patient Data Meta-Analysis evaluating Camostat Mesilate to Treat COVID-19 in Community Settings;2024-05-17

5. DON/DRP‐104 as potent serine protease inhibitors implicated in SARS‐CoV‐2 infection: Comparative binding modes with human TMPRSS2 and novel therapeutic approach;Journal of Cellular Biochemistry;2024-01-29